5-Hydroxytryptophan
Based on 2 publication(s) in Google Scholar
5-Hydroxytryptophan, a tryptophan metabolite, is a direct 5-hydroxytryptamine (5-HT) precursor and an L-aromatic amino acid decarboxylase substrate. .
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.89%
- CAS No.: 56-69-9
- Formule: C11H12N2O3
- Masse moléculaire:220.23
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) 5-Hydroxytryptophan
More
Customer Validation & Images
-
RT-PCR
-
RT-PCR
-
WB
-
IF
-
IP
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
MoreVoir tous les produits spécifiques à Isoform 5-HT Receptor
More
Activité biologique
|
Human Endogenous Metabolite |
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
5-Hydroxytryptophan (50-100 mg/kg, ip, single dose) increases the synthesis and release of 5-HT in the brain, thus activates 5-HT2 receptor and promotes the secretion of prolactin and ACTH in rats models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley rats[1]
-
Dosage:50-100 mg/kg
-
Administration:ip, single dose
-
Result:Increased the secretion of prolactin and ACTH.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 56-69-9
-
Appearance Solid
-
Masse moléculaire 220.23
-
Formule C11H12N2O3
-
Color White to off-white
-
SMILES
NC(CC1=CNC2=CC=C(O)C=C12)C(O)=O
-
Synonyms
5-HTP; DL-5-Hydroxytryptophan
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int J Biol Sci
Procyanidin Suppresses Tumor Growth by Activating the B-Cell MAPK Pathway through Remodulation of the Gut Microbiota and Metabolites in Hepatocellular Carcinoma. [Abstract]2026 Jan 1;22(1):161-177. PMID: 41362739 -
J Immunother Cancer
GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer. [Abstract]2021 Jul;9(7):e002383. PMID: 34281987
5-Hydroxytryptophan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2021 Jul;9(7):e002383. [Abstract]
Relative IDO1 transcription levels detected by quantitative reverse transcription PCR (qRT-PCR) analysis and IDO1 levels detected by western blot in BT549 cells treated with dimethyl sulfoxide (DMSO), tetrahydrobiopterin (BH4, 10 µM), 5-Hydroxytryptophan (5-HTP; 500 µM), serotonin (10 µM), NAS (100 µM), and melatonin (1 µM) for 24 hours.
5-Hydroxytryptophan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2021 Jul;9(7):e002383. [Abstract]
Relative IDO1 transcription levels detected by qRT-PCR analysis and IDO1 levels detected by western blot in BT549 cells treated with 5-Hydroxytryptophan (5-HTP; 0, 0.25, 0.5, 1, 2 μM) at different concentrations for 24 hours (Left) and with 5-HTP (500 µM) for different durations (0, 6, 12, 24, 48 h) (Right).
5-Hydroxytryptophan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2021 Jul;9(7):e002383. [Abstract]
BT549 cells treated with phosphate buffer saline (PBS) or 5-Hydroxytryptophan (5-HTP; 500 µM) for 24 hours.
5-Hydroxytryptophan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2021 Jul;9(7):e002383. [Abstract]
Representative immunofluorescence images of AHR and the cytoplasmic and nuclear protein fractions of the AHR protein in BT549 cells treated with phosphate buffer saline (PBS) or 5-HTP (500 µM) for 24 hours.
5-Hydroxytryptophan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2021 Jul;9(7):e002383. [Abstract]
Chromatin immunoprecipitation followed by quantitative PCR analysis of BT549 cells treated with 5-Hydroxytryptophan (5-HTP; 1 mM) for 48 hours.
5-Hydroxytryptophan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2021 Jul;9(7):e002383. [Abstract]
Analysis of luciferase activity in human embryonic kidney (HEK) 293 T cells. HEK-293 T cells concomitantly expressing an IDO1 promoter–luciferase reporter and AHR were treated with 5-Hydroxytryptophan (5-HTP; 500 µM) or PBS for 24 hours.
Solvant et solubilité
DMSO : 83.33 mg/mL (378.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 12.5 mg/mL (56.76 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (9.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (9.44 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 5.88 mg/mL (26.70 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 20 mg/mL (90.81 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Gartside SE, et al. Mediation of ACTH and prolactin responses to 5-HTP by 5-HT2 receptors. Eur J Pharmacol. 1990 Apr 10;179(1-2):103-9. [Content Brief]
[2]. Gijsman HJ, et al. Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers. J Clin Psychopharmacol. 2002 Apr;22(2):183-9. [Content Brief]
[3]. Schruers K, et al. Acute L-5-hydroxytryptophan administration inhibits carbon dioxide-induced panic in panic disorder patients. Psychiatry Res. 2002 Dec 30;113(3):237-43. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 4.5407 mL | 22.7037 mL | 45.4075 mL | 113.5187 mL |
| 5 mM | 0.9081 mL | 4.5407 mL | 9.0815 mL | 22.7037 mL | |
| 10 mM | 0.4541 mL | 2.2704 mL | 4.5407 mL | 11.3519 mL | |
| 15 mM | 0.3027 mL | 1.5136 mL | 3.0272 mL | 7.5679 mL | |
| 20 mM | 0.2270 mL | 1.1352 mL | 2.2704 mL | 5.6759 mL | |
| 25 mM | 0.1816 mL | 0.9081 mL | 1.8163 mL | 4.5407 mL | |
| 30 mM | 0.1514 mL | 0.7568 mL | 1.5136 mL | 3.7840 mL | |
| 40 mM | 0.1135 mL | 0.5676 mL | 1.1352 mL | 2.8380 mL | |
| 50 mM | 0.0908 mL | 0.4541 mL | 0.9081 mL | 2.2704 mL | |
| DMSO | 60 mM | 0.0757 mL | 0.3784 mL | 0.7568 mL | 1.8920 mL |
| 80 mM | 0.0568 mL | 0.2838 mL | 0.5676 mL | 1.4190 mL | |
| 100 mM | 0.0454 mL | 0.2270 mL | 0.4541 mL | 1.1352 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
5-Hydroxytryptophan Related Classifications
HY-N0122 Related Classifications
Powered by Bioz